Cullinan Therapeutics, Inc. $CGEM Stock Holdings Raised by Voss Capital LP

Voss Capital LP grew its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) by 43.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 251,717 shares of the company’s stock after purchasing an additional 76,717 shares during the quarter. Voss Capital LP’s holdings in Cullinan Therapeutics were worth $1,895,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Cullinan Therapeutics by 3.5% in the first quarter. Vanguard Group Inc. now owns 3,039,731 shares of the company’s stock valued at $23,011,000 after buying an additional 103,504 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Cullinan Therapeutics by 0.4% during the 2nd quarter. Franklin Resources Inc. now owns 2,228,160 shares of the company’s stock worth $16,778,000 after buying an additional 8,399 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Cullinan Therapeutics by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,279,496 shares of the company’s stock worth $9,636,000 after buying an additional 37,679 shares during the last quarter. Marshall Wace LLP grew its position in shares of Cullinan Therapeutics by 10.3% in the 2nd quarter. Marshall Wace LLP now owns 626,581 shares of the company’s stock worth $4,718,000 after acquiring an additional 58,582 shares in the last quarter. Finally, Algert Global LLC grew its position in shares of Cullinan Therapeutics by 411.5% in the 1st quarter. Algert Global LLC now owns 221,430 shares of the company’s stock worth $1,676,000 after acquiring an additional 178,138 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 4,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $12.30, for a total value of $49,200.00. Following the completion of the transaction, the insider owned 138,004 shares in the company, valued at approximately $1,697,449.20. This represents a 2.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lynx1 Capital Management Lp purchased 626,043 shares of the company’s stock in a transaction on Thursday, October 9th. The stock was purchased at an average price of $6.70 per share, for a total transaction of $4,194,488.10. Following the purchase, the insider directly owned 8,271,786 shares of the company’s stock, valued at $55,420,966.20. This trade represents a 8.19% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 1,874,057 shares of company stock valued at $13,325,286 over the last three months. 6.07% of the stock is currently owned by company insiders.

Cullinan Therapeutics Price Performance

Shares of NASDAQ CGEM opened at $10.59 on Monday. The firm has a market capitalization of $625.66 million, a PE ratio of -3.20 and a beta of -0.11. Cullinan Therapeutics, Inc. has a 1-year low of $5.68 and a 1-year high of $13.60. The business’s fifty day moving average price is $8.35 and its two-hundred day moving average price is $7.91.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.18. Equities research analysts expect that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

CGEM has been the topic of several research reports. BTIG Research upped their price target on Cullinan Therapeutics from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Zacks Research upgraded shares of Cullinan Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 16th. Wall Street Zen raised shares of Cullinan Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Cullinan Therapeutics in a report on Thursday, November 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Monday, December 1st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Cullinan Therapeutics Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.